Analysts Offer Predictions for AURA Q1 Earnings

Aura Biosciences, Inc. (NASDAQ:AURA) – Equities research analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Aura Biosciences in a report issued on Tuesday, August 11th. HC Wainwright analyst A. Maldonado forecasts that the company will earn ($0.40) per share for the quarter. HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.73) per share. HC Wainwright also issued estimates for Aura Biosciences’ Q2 2027 earnings at ($0.40) EPS, Q3 2027 earnings at ($0.41) EPS and Q4 2027 earnings at ($0.42) EPS.

A number of other equities research analysts have also issued reports on AURA. Wall Street Zen upgraded Aura Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday. Leerink Partners set a $17.00 target price on shares of Aura Biosciences in a research note on Tuesday, May 12th. Finally, Weiss Ratings raised Aura Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 14th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $17.50.

Aura Biosciences Stock Performance

AURA opened at $8.04 on Wednesday. Aura Biosciences has a 1 year low of $4.73 and a 1 year high of $9.53. The firm has a 50 day moving average price of $6.96 and a 200 day moving average price of $6.71. The company has a market cap of $831.66 million, a PE ratio of -4.62 and a beta of 0.40.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.10).

Institutional Investors Weigh In On Aura Biosciences

Large investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC grew its position in Aura Biosciences by 49.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock worth $40,000 after purchasing an additional 2,104 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Aura Biosciences by 12.3% in the third quarter. JPMorgan Chase & Co. now owns 24,557 shares of the company’s stock valued at $152,000 after purchasing an additional 2,693 shares during the period. Parallel Advisors LLC raised its holdings in shares of Aura Biosciences by 130.4% during the first quarter. Parallel Advisors LLC now owns 5,665 shares of the company’s stock valued at $38,000 after buying an additional 3,206 shares during the last quarter. Barclays PLC raised its holdings in shares of Aura Biosciences by 6.7% during the fourth quarter. Barclays PLC now owns 69,298 shares of the company’s stock valued at $378,000 after buying an additional 4,366 shares during the last quarter. Finally, Intech Investment Management LLC raised its holdings in shares of Aura Biosciences by 35.9% during the fourth quarter. Intech Investment Management LLC now owns 20,993 shares of the company’s stock valued at $114,000 after buying an additional 5,541 shares during the last quarter. 96.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Aura Biosciences

In other news, insider Anthony S. Gibney sold 12,824 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $6.42, for a total transaction of $82,330.08. Following the completion of the transaction, the insider directly owned 265,354 shares of the company’s stock, valued at approximately $1,703,572.68. This represents a 4.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 1.90% of the company’s stock.

Trending Headlines about Aura Biosciences

Here are the key news stories impacting Aura Biosciences this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and set an $18 price target for Aura Biosciences (AURA). Although the target was reduced from $24, it still implies significant upside from the recently cited $8.04 share price. The firm expects ongoing quarterly losses of approximately $0.40 to $0.42 per share through 2027. Benzinga analyst target report
• Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day days-to-cover ratio. This suggests the available data does not indicate meaningful short-selling pressure, though the figures may reflect incomplete or anomalous reporting rather than a major change in investor positioning.
• Negative Sentiment: Aura reported a second-quarter 2026 loss of $0.48 per share, wider than the consensus estimate of a $0.38 loss. The earnings miss reinforces concerns about near-term cash burn and profitability. Aura Biosciences second-quarter earnings release
• Negative Sentiment: The company is cutting approximately 20% of its workforce and changing its executive leadership team as it refocuses research and development on eye-cancer programs. The restructuring may reduce expenses, but it also signals operational pressure and could raise execution concerns in the near term. Aura workforce reduction and R&D refocus

About Aura Biosciences

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.